Status:
COMPLETED
Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
Eligibility Criteria
Inclusion
- Men and women
- 18 to 75 yrs old
- Motivated to stop smoking
- Smoke at least 10 cigarettes/day
Exclusion
- Active psychiatric disease
- Severe or unstable cardiovascular or pulmonary disease
- Current or recent treatment to stop smoking
- Previous use of varenicline
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
659 Patients enrolled
Trial Details
Trial ID
NCT00691483
Start Date
September 1 2008
End Date
December 1 2009
Last Update
November 20 2015
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Litchfield Park, Arizona, United States, 85340
2
Pfizer Investigational Site
Los Angeles, California, United States, 90095
3
Pfizer Investigational Site
Santa Ana, California, United States, 92705
4
Pfizer Investigational Site
Overland Park, Kansas, United States, 66212